drugset / Trial / NCT06731075

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

NCT06731075 ↗

Phase 3 Not yet recruiting 300 enrolled Oramed, Ltd. InClin, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering medications. A total of three hundred subjects will be enrolled in this study and will be required to complete this thirty-four-week clinical trial.

Timeline

Start
2025-12-15
Primary completion
2027-04-25
Completion
2027-05-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator ORMD-0801 Protein / enzyme biologic 8 mg Oral
Comparator ORMD-0801 Protein / enzyme biologic 16 mg Oral